West Pharmaceutical Services (WST) Receivables - Net (2009 - 2026)

West Pharmaceutical Services has disclosed Receivables - Net across 18 years of filings, most recently posting $712.0 million for Q2 2026.

• In Q2 2026, Receivables - Net rose 22.25% year-over-year to $712.0 million; the TTM figure through Jun 2026 stood at $712.0 million (up 22.25% YoY), while the FY2025 annual figure was $574.4 million, up 3.96% from the prior year.
• Receivables - Net came in at $712.0 million for Q2 2026 at West Pharmaceutical Services, up from $685.6 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $712.0 million in Q2 2026 to a low of $479.4 million in Q2 2024.
• Average Receivables - Net over 5 years is $550.1 million, with a median of $526.4 million recorded in 2022.
• Year-over-year, Receivables - Net declined 10.29% in 2024 and grew 26.12% in 2026.
• Over 5 years, Receivables - Net stood at $507.4 million in 2022, then grew by 0.91% to $512.0 million in 2023, then grew by 7.91% to $552.5 million in 2024, then rose by 3.96% to $574.4 million in 2025, then climbed by 23.96% to $712.0 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $712.0 million in Q2 2026, $685.6 million in Q1 2026, and $574.4 million in Q4 2025.